These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 31097091)

  • 1. The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma.
    Wang H; Agulnik J; Kasymjanova G; Fiset PO; Camilleri-Broet S; Redpath M; Cohen V; Small D; Pepe C; Sakr L; Spatz A
    Lung Cancer; 2019 Jun; 132():36-38. PubMed ID: 31097091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world prevalence of PD-L1 expression in non-small cell lung cancer: an Australia-wide multi-centre retrospective observational study.
    Russell PA; Farrall AL; Prabhakaran S; Asadi K; Barrett W; Cooper C; Cooper W; Cotton S; Duhig E; Egan M; Fox S; Godbolt D; Gupta S; Hassan A; Leslie C; Leong T; Moffat D; Qiu MR; Sivasubramaniam V; Skerman J; Snell C; Walsh M; Whale K; Klebe S
    Pathology; 2023 Dec; 55(7):922-928. PubMed ID: 37833206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.
    Herbst RS; Baas P; Perez-Gracia JL; Felip E; Kim DW; Han JY; Molina JR; Kim JH; Dubos Arvis C; Ahn MJ; Majem M; Fidler MJ; Surmont V; de Castro G; Garrido M; Shentu Y; Emancipator K; Samkari A; Jensen EH; Lubiniecki GM; Garon EB
    Ann Oncol; 2019 Feb; 30(2):281-289. PubMed ID: 30657853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of PD-L1 22C3 IHC pharmDxTM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation.
    Lou SK; Ko HM; Kinoshita T; MacDonald S; Weiss J; Czarnecka-Kujawa K; Boerner SL; Yasufuku K; Tsao MS; Schwock J
    Acta Cytol; 2020; 64(6):577-587. PubMed ID: 32599583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States.
    Velcheti V; Patwardhan PD; Liu FX; Chen X; Cao X; Burke T
    PLoS One; 2018; 13(11):e0206370. PubMed ID: 30408065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity in PD-L1 expression between primary and metastatic lymph nodes: a predictor of EGFR-TKI therapy response in non-small cell lung cancer.
    Hu Y; Zhang Y; Lu Y; Xu Y; Xu J; Zhong H; Cheng L; Zhong R
    Respir Res; 2024 Jun; 25(1):233. PubMed ID: 38840238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological characteristics and tumor infiltrating immune cells associations of PD-L1 tumor expression in non-small cell lung cancer patients.
    Aazzane O; Bakhtaoui FZ; Stitou S; Fellah H; Karkouri M
    Tunis Med; 2024 Apr; 102(4):223-228. PubMed ID: 38746962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study.
    Yang JJ; Huang C; Fan Y; Pan H; Feng J; Jiang L; Li XY; Liu XQ; Xiong JP; Zhao YQ; Cheng Y; Ma R; Wang J; Wang Y; Liu YH; Lin DM; Wang T; Shi W; Zou J; Wu YL
    Cancer Immunol Immunother; 2022 Jun; 71(6):1393-1402. PubMed ID: 34668977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of primary and metastatic site-related PD-L1 expression in predicting ORR in patients with advanced NSCLC who received ICB-based therapy.
    Zhou D; Wang Y; Ning W; Chen C
    Thorac Cancer; 2024 Feb; 15(5):379-385. PubMed ID: 38155421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer.
    Koomen BM; van der Starre-Gaal J; Vonk JM; von der Thüsen JH; van der Meij JJC; Monkhorst K; Willems SM; Timens W; 't Hart NA
    Cancer Cytopathol; 2021 Apr; 129(4):304-317. PubMed ID: 33108706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment selection and real-world analysis of immunotherapy with or without chemotherapy in PD-L1-high metastatic non-small cell lung cancer.
    Smith S; Kao S; Boyer M; Franco M; Moore M
    Intern Med J; 2024 Aug; 54(8):1337-1343. PubMed ID: 38622825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 Assessment in Needle Core Biopsies of Non-Small Cell Lung Cancer: Interpathologist Agreement and Potential Associated Histopathological Features.
    Hacihasanoglu E; Bambul Sigirci B; Usul G; Savli TC
    Turk Patoloji Derg; 2024; 40(1):37-44. PubMed ID: 37614090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?
    Torous VF; Rangachari D; Gallant BP; Shea M; Costa DB; VanderLaan PA
    J Am Soc Cytopathol; 2018; 7(3):133-141. PubMed ID: 29713584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 expression in fine-needle aspiration cell blocks of head and neck squamous-cell carcinoma and its cytohistological concordance.
    Lou SSK; Ruff H; MacDonald S; Smith SM; Cheung CC
    Diagn Cytopathol; 2024 Mar; 52(3):163-170. PubMed ID: 38095142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trajectory of PD-L1 expression in a patient underwent neoadjuvant chemo-immunotherapy for resectable NSCLC.
    Gallina FT; Balzano V; Porciello N; Tajè R; Forcella D; Melis E; Letizia Cecere F; Fusco F; Buglioni S; Visca P; Nisticò P; Cappuzzo F; Spicer J
    Lung Cancer; 2024 Aug; 194():107900. PubMed ID: 39079181
    [No Abstract]   [Full Text] [Related]  

  • 16. Accuracy of Cytologic vs Histologic Specimens for Assessment of Programmed Cell Death Ligand-1 Expression in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Tajarernmuang P; Aliaga F; Alwakeel AJ; Tavaziva G; Turner K; Menzies D; Wang H; Ofiara L; Benedetti A; Gonzalez AV
    Chest; 2024 Feb; 165(2):461-474. PubMed ID: 37739030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.
    Garon EB; Cho BC; Luft A; Alatorre-Alexander J; Geater SL; Trukhin D; Kim SW; Ursol G; Hussein M; Lim FL; Yang CT; Araujo LH; Saito H; Reinmuth N; Kohlmann M; Lowery C; Mann H; Peters S; Mok TS; Johnson ML
    Clin Lung Cancer; 2024 May; 25(3):266-273.e5. PubMed ID: 38584069
    [No Abstract]   [Full Text] [Related]  

  • 18. PD-L1 expression in ovarian clear cell carcinoma using the 22C3 pharmDx assay.
    Gao Y; Pan B; Jia H; Zhang Y; Wang S; Wang Y; Zhang S; Li M; Wang A; Wang X; Zhao K; Zhang Z; Sun J; Guo D; Liang Z
    Diagn Pathol; 2024 Jun; 19(1):82. PubMed ID: 38879528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-cancer analysis of
    Huang RSP; Decker B; Murugesan K; Hiemenz M; Mata DA; Li G; Creeden J; Ramkissoon SH; Ross JS
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34130989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The detection of PD-L1 expression on liquid-based cytology in pleural effusion of lung adenocarcinoma and its prognostic evaluation: Between paired liquid-based cytology and cell block samples.
    Ma H; Jia J; Sun Z; Xiao X; Liang S; Zhao L; Zhang Z
    Diagn Cytopathol; 2024 May; 52(5):235-242. PubMed ID: 38263766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.